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Abstract Access to an optimal treatment is determined by
several factors, like availability, pricing/funding, and accept-
ability. In Latin America (LA), one of the regions with more
disparities particularly on healthcare in the world, access is
affected by other factors, including socio-demographic factors
like poverty, living in rural regions, and/or health coverage.
Regarding rheumatoid arthritis (RA), an inadequate access to
specialists leads to diagnosis and treatment delays diminishing
the probability of remission or control. Unfortunately, in al-
most every LA country, there are cities with more than 100,
000 inhabitants without rheumatologists; furthermore, a pri-
mary care reference system is present in only about half the
countries. In the public health system, coverage of biologic
disease-modifying antirheumatic drugs occurs for less than
10 % of the patients in about half of the countries. Also, as
healthcare providers based their funding decisions mainly in
direct costs instead of on patient-centered healthcare quality
indicators, access to new drugs is more complicated in this
region than in high-income countries. More accurate epidemi-
ological data from LA need to be obtained in order to improve
the management of patients with rheumatic diseases in general
and RA in particular.
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Introduction
The World Health Organization has defined access and use of
healthcare services as one of the determinants of health [1]; in
rheumatoid arthritis (RA), patient-centered healthcare quality
indicators (HCQI) include access to care and pharmacological
treatment [2].
RA is a chronic autoimmune disease, which may lead to
functional disability resulting in high personal and societal
economic impact. Access to optimal treatments is needed in
order to reduce this burden. Early diagnosis and treatment are
necessary to achieve optimal outcomes; early treatment has
been associated with a 33 % reduction of radiographic pro-
gression compared to delayed treatment [3]. Furthermore,
combination therapy and intensive treatment like tight control
or treat-to-target (T2T) have been associated with a lower rate
of disease progression than monotherapy or non-T2T ap-
proaches [4, 5]. These data indicate that RA patients need an
efficient healthcare system, which should include an early
primary care referral base, well-equipped laboratories and im-
aging departments, access to a health professional team led by
a rheumatologist, and several treatment options [including
synthetic and biologic disease-modifying antirheumatic drugs
(DMARDs)]. In general, the worldwide Joint Learning Initia-
tive has proposed that overall 2.5 healthcare workers per 1000
inhabitants is an acceptable standard [6]. Regarding rheumatic
diseases, at least in the UK, the recommended relationship
between rheumatologists and inhabitants is 1/85,000 [7].
In this review, we will examine the importance of an
adequate access to treatment and the current situation in
Latin America (LA).
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Determinants of access
Access to treatment is determined by several factors, including
availability, pricing/funding, and acceptability (Fig. 1). Avail-
ability is affected by market size and health policies related to
low income and a low percentage of the gross domestic prod-
uct (GDP) allocated to health budgets. In a recent report from
Europe, non-members of the European Union (EU) had a
lower number of biologic DMARDs approved and even a
lower number of biologic DMARDs reimbursed [8]. In addi-
tion, the numbers of biologic DMARDs approved and reim-
bursed are positively correlated with the per capita GDP, me-
dian income, and total health expenditures [8]. If we extrapo-
late these data to LA, it should be expected that overall they
will have a lower number of biologic DMARDs approved and
reimbursed. Availability also relates to accessibility to
healthcare and to drugs; in Portugal, key barriers for access
to healthcare and treatment (particularly biologic DMARDs)
were found to be related to accessibility to primary care ser-
vices, difficulties in the diagnosis of RA by general practi-
tioners, an inefficient referral system, and a cumbersome ad-
ministrative process for the prescription of biologic DMARDs
[9]. In Greece, 26 % of the patients had obstacles in accessing
a rheumatologist, mainly due to delays in scheduling an ap-
pointment or difficulties in traveling to and from the clinic. On
the other hand, 49% of the patients had problems in accessing
their medications, mainly due to administrative difficulties
and drug non-availability [10]. In Canada, of patients referred
with probably RA, possible RA or probably osteoarthritis,
about one third were evaluated within 3 months of the referral,
another third beyond the first 3 months and the last third were
refused evaluation because rheumatologists were not
accepting new patients at the time of the referral. Overall,
40 % of patients with possible or probable RAwere evaluated
by a rheumatologist within 3 months of the referral from the
primary care provider. This percentage decreased to 30 % for
patients living in small towns [11].
Pricing/funding is particularly important in low-income
countries; for example, in eastern European countries, the ra-
tio between the cost of biologic DMARDs and health expen-
ditures per capita was between three- and six-fold higher than
in western European countries [12]. Furthermore, the average
price, adjusted for the countries’ purchasing power parity, as
well as the average expenditure per patient were negatively
associated with the per capita GDP, median income, and total
health expenditure. Also, the average price and average per
patient expenditure positively correlated with disease activity
and disability, as measured by the disease activity score
(DAS28) and the health assessment questionnaire (HAQ), re-
spectively [8]. In Europe, also, the proportion of patients using
biologic DMARDs correlated with the GDP, and this propor-
tion ranged from 7 % (Portugal) to more than 30 % in Ireland
and the Netherlands; Portugal had a GDP of USD 23,100 and
Ireland and the Netherlands of around USD 40,000 [13]. In a
comparison between RA databases, the initiation of anti-TNF
compounds seems to be related to reimbursement and physi-
cian practices/preferences [14]. A higher household income is
associated with a higher probability of starting a biologic
DMARD [15]. Even more disease activity is negatively asso-
ciated with the GDP per capita [16, 17]. These data, taken
together, suggest that living in a low-income country should
be considered a risk factor for bad prognosis for RA patients.
Acceptability is a more complex concept, and it includes
physician’ and patient’s barriers. In the case of physician’s
barriers, they could be affected by the healthcare system, in-
cluding administrative and financial constraints and by the
physician’s knowledge and beliefs about biologic DMARDs.
For example, even though current guidelines recommend low
disease activity as a goal to achieve for all RA patients, more
than one third of the patients with moderate or high disease
activity did not have a modification on their DMARD therapy
in Australia, being the main reasons for not making any mod-
ification the presence of irreversible joint damage (19.7 %),
patient-driven under-treatment (14.7 %), and rheumatologist-
driven under-treatment (9.9 %) [18]. Patient’s barriers include
access to the healthcare system (in particular to the rheuma-
tologist), affordability (amount of individual contribution to
treatment), and lack of trust in the system and on the drugs
(including some region-related myths). In Europe,
administrative/financial barriers for prescribers and patients’
lack of trust into the healthcare system are negatively associ-
ated with the per capita GDP, median income, and total health
expenditure, but other factors of acceptability are not [8].
Demographic factor related to access to treatment
Access to healthcare is also affected by patients’ demographic
factors; for example, patients older than 65 years have less
knowledge about the nature and prognosis of the disease and
the side effects of the medications [19]. Regarding healthcare
utilization, medical specialist services are more frequently
used by younger patients, those with longer disease duration,
with poorer functional status, and with a high number of co-
morbidities [20]. Furthermore, cost-related non-adherence in
older patients is associated with lower income and lower pre-
scription coverage and is higher in RA patients than in patients
with other chronic conditions. In addition, RA patients invest
less in basic needs in order to afford their medications [21].
Lower level of education has been associated with higher
disease activity in a multinational study [17]. Patients with a
low level of education also have less knowledge about the
nature and prognosis of the disease and side effects of the
drugs [19] and use biologic DMARDs less frequently than
those with higher levels of education [22]. In LA, low level
of education has been associated with less treatment
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adherence including patient difficulties in remembering the
doses of their medications and/or how frequently they should
take them, forgetting to take their medications, and/or decreas-
ing the dosages prescribed [23]. Furthermore, low level of
health literacy has been associated with higher level of disease
activity in multicenter study in Argentina [24]. The largest
early RA multiethnic cohort from LA (Grupo Latino
Americano de Estudio de Artritis Reumatoide, GLADAR)
has shown that almost 60 % of the patients are from the low
and middle-low socioeconomic levels and that lower socio-
economic status is associated with higher baseline disease
activity [25], but with less use of biologic DMARDs [22].
Strategies related to access to treatment
Primary care for RA patients
To achieve the goal of early diagnosis and treatment for all RA
patients, an efficient referral system is needed. RA patient who
receive care by an internist or a primary care physician is less
likely to receive a DMARD than those who see a rheumatol-
ogist. In addition, those patients treated by rheumatologists, in
particular those treated continuously, use more consistently
DMARDs and are more frequently on a combination therapy.
Even more so, methotrexate is more commonly used among
those patients treated continuously by a rheumatologist [26].
Only 60 % of primary care physicians considered that
DMARDs should be started within the first 6 months of diag-
nosis, 61 % felt uncomfortable starting DMARDs, and 71 %
were likely to refer RA patients to specialists, although the
most frequent reason for the referral was advanced disease
(80 %). Among the reasons for not referring, 40 % did not
refer due to insurance problems, 27 % considered a rheuma-
tology appointment too difficult to obtain, and 24 % consid-
ered patient did not need a referral [27]. This lack of accessi-
bility to a rheumatologist and the inadequate treatment by
internists and/or primary care physicians carries a poor prog-
nosis for these patients. In Canada, access to a rheumatologist
for patients with inflammatory arthritis and any arthritis was
found to be associated with a better socioeconomic status and
access to primary care physician [28].
In order to improve access to rheumatologists, several strat-
egies have been developed. One of them is to use the Amer-
ican College of Rheumatology/European League against
Rheumatism (ACR/EULAR) criteria as a prioritization tool.
Using it, the time for referral could be reduced to 8 weeks
compared to 45 weeks for those patients who did not meet
these criteria which gave a sensitivity of 96 %, a specificity of
56 %, a positive predictive value of 40 %, and a negative
predictive value of 98 % [29]. Another strategy is the use of
a questionnaire administered by a nurse practitioner; based on
it, the decision of which patients referred by general practi-
tioner requires an urgent referral; this strategy had a sensitivity
of 97 %, a specificity of 55 %, a positive predictive value of
49 %, and a negative predictive value of 97 % [30]. A self-
administered tool, which could lead to earlier references with-
out increasing the number of primary care health profes-
sionals, had a higher specificity (87 %) but a lower sensitivity
of 86 % [31].
Patient-centered healthcare quality indicators
Access to treatment should be defined not only by the physi-
cian’s opinion but should also include the patient’s preferences
and needs. In order to do that, patient-centered healthcare
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quality indicators (HCQIs) have recently been proposed for
the provision of healthcare to RA patients. A final set of 14
indicators has been developed to be used in quality improve-
ment and benchmarking in countries across Europe. Among
them, two indicators were established for structure (patient
information and calculation of composite scores), 11 for pro-
cess (e.g., access to care, assessments, and pharmacological
and non-pharmacological treatments), and one for outcome
(effect of treatment on disease activity, including the goal of
at least low disease activity after 6 months of treatment). Re-
garding process indicators, they include the time between the
onset of symptoms and the evaluation by specialist (it should
be not more than 6 weeks), the time between the onset of
symptoms and a tailored education by health professionals
as well as an individualized exercise program (not more than
3 months), the time between orthopedic surgeon evaluation,
and the presence of joint damage/soft tissue problems that
may require surgery (not more than 3 months); others in this
category are assessment of disease activity, damage, quality of
life, labor force participation, response to treatment (and ad-
justment according to EULAR guidelines) [2]. Unfortunately,
in LA, these indicators are barely accomplished due to the
well-documented delays between the primary-care and the
specialist’s evaluation.
Treat to target, tight control strategies
Another pathway to use more efficiently scarce resources is to
define treatment’s goals and strategies and follow guidelines
which suggest how the treatment should be increased or de-
creased. Treatment strategies have been changed in the last
few years due to the existence of new drug- and protocol-
driven studies. These protocol-driven studies include an inten-
sive treatment adjusted according to a predefined outcome
measured by a composite disease activity index (usually re-
mission or low disease activity). The systematic use of a dis-
ease activity index has led to a high proportion of patients
achieving low levels of disease activity compared to those
patients in whom this index had not been used [32]. Among
protocol-driven studies, the tight control for rheumatoid arthri-
tis (TICORA) study compared routine care against intensive
care (monthly assessments and if low disease activity was not
achieved, treatment was increased). Patients from the inten-
sive care group had a higher rate of remission and less radio-
graphic progression than those in the routine care group [33].
The Computer-Assisted Management in Early Rheumatoid
Arthritis (CAMERA) study evaluated a computerized
decision-making program of monthly evaluations for the in-
tensive care group with a predefined treatment scheme and
every 3 months for the conventional treatment group; treat-
ment adjustments were done according to joint counts and
assessors’ judgment in this group. After 2 years, the intensive
care group had a higher percentage of remission, but a similar
radiographic progression than the routine care group [34]. In
Colombia, the T2T strategy has shown a decrease in disease
activity in 80 % of the patients using traditional DMARDs
[35], and in Brazil, the T2T strategy was associated with
20.4 % of remission, compared to 12.6 % before using T2T
strategy [36].
According to these studies, tight control proved to be asso-
ciated with a better treatment response and it should be includ-
ed as a predefined end-point by rheumatologists until it is
achieved. According to EULAR recommendations Btreatment
should be aimed at reaching a target of remission or low dis-
ease activity as soon as possible in every patient; and as long
as the target has not been reached, treatment should be adjust-
ed by frequent (every 1–3 months) and strict monitoring^ [37,
38].
Protocol-driven studies have also lead to the proposal of the
T2T strategy which included an end-point (remission or low
disease activity) and more frequent evaluations (monthly)
when the patient has moderate or high disease activity or less
frequent when the goal is achieved [39].
Cost/effectiveness and cost/utility
Cost/effectiveness is a decision-making criterion for the ma-
jority of health insurance systems; however, it is important to
point out that several outcomes have been chosen in order to
define effectiveness. One of the most used is the quality-
adjusted life-year (QALY), which combines life expectancy
and quality of life (QoL) by weighting life-years with a quality
index [40]. However, as QoL is influenced by disease activity
and damage, the earlier the intervention is performed, the
higher the opportunity of a better QoL. Furthermore, an offi-
cial threshold to be considered Bcost/effective^ has not been
established, but if 50,000 € per QALY (a commonly accepted
threshold) is considered, biologic DMARDs do achieve this
goal [40].
Cost analyses are complex, because they should not in-
clude merely direct costs. RA-related costs include productiv-
ity losses and, even, the cost of the investment through edu-
cation, work experience, and job training; this approach is
named Bthe human capital method.^ Using this method, the
cost of biologic DMARDS could be compensated by savings
in productivity [41].
The majority of the cost/effectiveness studies have been
performed in the developed world. In low-income countries,
this type of analysis is more complicated because the cost of
the drugs is similar; yet, the return by improving worker par-
ticipation would be lower (due to the lower labor value). This
situation could lead to a vicious circle, which makes even
more complicated the access to an adequate treatment for
RA patients in these countries. In addition, even in developed
countries, cost/effectiveness and cost/utility evidence is not
weigh ted in the same way, and off i c ia l d rugs ’
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recommendations include other factors that alter an adequate
use of high-quality evidence [42].
Currently, almost all health insurance systems use cost/
effectiveness as the only criterion in order to define which
patients should or should not use biologic DMARDs; howev-
er, if indirect costs are not included, this strategy turns into a
barrier for an access to an optimal treatment.
Latin America. Current situation
Several economic- and healthcare system-related factors are
associated with access to treatment, and these factors are of
particular interest in LA. Gross national income per capita,
adjusted by purchasing power parity in LA, is just 25 % of
the USA (USD 12,086 vs. 50,610, respectively), but in Haiti,
it is only USD 1240; it means that the cost of current biolog-
ical treatments per year is higher than the average income per
capita in LA. The quintile with the higher income level earns
16 times more per year than those of the lower quintile. This
difference is even more dramatic in Panama where this rela-
tionship is almost 30 [43].
There are high disparities in terms of the healthcare system
between and within the different LA countries. For example,
the proportion of medical doctors per 10,000 inhabitants for
the entire region is 17.5. As an average, this proportion is
adequate; however, it ranges from 4.2 for Bolivia to 68.1 for
Cuba. Thus, the distribution of physician within LA needs to
improve, and, in some countries, their actual number needs to
increase. Among LA countries, the proportion of rheumatol-
ogists per 100,000 inhabitants was 0.7 (range from 0.1 for
Nicaragua to 3.2 for Uruguay); furthermore, only Argentina
and Uruguay had more than 1 rheumatologist per 85,000 in-
habitants [44, 45]; these data are depicted in Table 1. Like-
wise, the health system coverage ranges from 22 % for Para-
guay to 100 % for Argentina, Brazil, and Cuba [43]. In addi-
tion, the expenditures in the public healthcare system defined
as percentage of GDP ranges from 2.4 % in Guatemala to
5.4 % in Uruguay [43] with an average of 3.8 % for the entire
region.
In Mexico, only 19 % of RA patients started DMARD
within first 3 months from symptoms onset, and 24 %
after 1 year [46]; in Venezuela, mean lag time between
symptom onset and the beginning of DMARDs was al-
most 5 years [47]; in two Argentine centers, from 2004 to
2007, median lag time between symptom onset and the
beginning of DMARDs was 4 months but with an inter-
quartile rank from 1 to 24 months [48], and in an Argen-
tine multicenter early arthritis cohort (which began in
2008), all patients with RA started DMARDs within the
first 6 months [49]. Almost 50 % of a Mexican early RA
cohort did not have adequate treatment compliance, and
main reasons were drug availability and costs [50]. Health
expenses higher than 30 % of the total house income are
associated with a lower level of health coverage and dis-
ease duration, and impoverishment is associated with a
higher health expense and disability and lower socioeco-
nomic status [51].
Recently, and aiming at this publication, the Pan American
League of Associations for Rheumatology (PANLAR) has
conducted a survey of LA rheumatologists thru the national
societies of the countries from the region; each national soci-
ety sent the questionnaire to its members. Two hundred and
twelve individual responses were obtained and analyzed; this
survey reveals that rheumatologists are distributed mainly in
urban regions and in large cities; more than 95 % considered
that the majority of rheumatologists are in cities with at least
100,000 inhabitants, and a similar percentage considered that
there are regions within their countries without access to a
specialist. In addition, more than 90 % of participants agreed
that there are second and third level hospitals that do not have
a rheumatologist and that only 50 % of patients have access to
a free evaluation in the public healthcare system. Even more, a
primary care reference system only exists in 50% of the coun-
tries, according to the same survey.
Because of the rheumatologists’ geographical distribution
in towns and cities, the long distances between them, and the
inadequate number of rheumatologists in several LA coun-
tries, it would be difficult for RA patients from rural regions
or small towns to be evaluated by a rheumatologist; for exam-
ple, in Costa Rica, there is a 4- to 6-month delay for an eval-
uation by a rheumatologist which results in patients missing
the Bwindow of opportunity^ in the treatment of this condition
[52].
The availability of traditional DMARDs is almost
100 %, but for the biologic DMARDs including
tofacitinib, it ranges from 72.4 % (tofacitinib) to
96.1 % (anti-TNF). Among the 212 LA rheumatologists,
almost 50 % consider that the coverage for biologic
DMARDs occurs for less than 10 % of the patients in
the public healthcare system and within them even
worse for tofacitinib. In the social security system, less
than 50 % of rheumatologists consider that coverage is
over 90 % and among the private insurance system less
than 40 % reported coverage over 90 %. Furthermore,
less than 60 % of the rheumatologists use T2T or tight
control strategies.
Taking all these data together, the access to an optimal
treatment for patients with RA in LA is far from being accept-
able, situation which is definitively worse for patients of low
socioeconomic status.
Conclusions
1. RA is a chronic inflammatory disease, which leads to
disability, having a high individual and societal economic
Clin Rheumatol (2015) 34 (Suppl 1):S59–S66 S63
impact. This is particularly true in less-developed coun-
tries like those in LA, and in particular in those popula-
tions with limited access to healthcare; however, there is
scarce information about access to treatment in LA.
2. Inequities in the access to an optimal treatment in LA
include not only the lack of drugs, particularly of biolog-
ical DMARDs, but also less access to specialists which is
particularly the case for marginal and rural populations.
3. Early diagnosis and management need to be improved,
using prioritization tools for early reference and T2T and
tight control strategies until remission or low disease ac-
tivity are achieved.
4. Determinants of access to treatment, including approval
process, pricing decision and funding need to be im-
proved in LA.
5. Health policy about access to treatment should not be
based merely on costs but should include patient-
centered HCQI as well as the societal impact of disease.
6. In most LA countries, healthcare budgets, by neces-
sity, cover the most frequent pathologies like infec-
tious diseases and maternal/infant problems as prior-
ities leaving chronic diseases including the rheumat-
ic diseases way behind them. In LA, we need more
epidemiological and health economic studies to
quantify the impact of rheumatic diseases, including
RA in the different countries of the region and to
achieve a more equitable allocation of funds for the
optimal treatment of the population affected.
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